By: Benzinga
Canaccord Genuity Reiterates Buy Rating, $100 PT on Watson Pharmaceuticals
In a report published Monday, Canaccord Genuity reiterated its Buy rating and $100.00 price target on Watson Pharmaceuticals (NYSE: WPI ). Canaccord Genuity noted, “It was announced this morning that Mallinckrodt (subsidiary of Covidien) has received FDA approval for the 27, 36 and 54 mg dosage strengths of Concerta ER
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here